consent form cancer research uk

Together we are beating cancer

About cancer

Cancer types

• Breast cancer
• Bowel cancer

Lung cancer

• Prostate cancer

Cancers in general

• Clinical trials

Causes of cancer

Coping with cancer

• Managing symptoms and side effects
• Mental health and cancer
• Money and travel
• Death and dying
• Cancer Chat forum

Health Professionals

• Cancer Statistics
• Cancer Screening
• Learning and Support
• NICE suspected cancer referral guidelines

Get involved

• Make a donation

By cancer type

• Leave a legacy gift
• Donate in Memory

Find an event

• Race for Life
• Charity runs
• Charity walks
• Search events
• Relay For Life
• Volunteer in our shops
• Help at an event
• Help us raise money
• Campaign for us

Do your own fundraising

• Fundraising ideas
• Get a fundraising pack
• Return fundraising money
• Fundraise by cancer type
• Set up a Cancer Research UK Giving Page
• Find a shop or superstore
• Become a partner
• Cancer Research UK for Children & Young People
• Our We Are campaign

Our research

• Brain tumours
• Skin cancer
• All cancer types

By cancer topic

• New treatments
• Cancer biology
• Cancer drugs
• All cancer subjects
• All locations

By Researcher

• Professor Duncan Baird
• Professor Fran Balkwill
• Professor Andrew Biankin
• See all researchers
• Our achievements timeline
• Our research strategy
• Involving animals in research

Funding for researchers

Research opportunities

• For discovery researchers
• For clinical researchers
• For population researchers
• In drug discovery & development
• In early detection & diagnosis
• For students & postdocs

Our funding schemes

• Career Development Fellowship
• Discovery Programme Awards
• Clinical Trial Award
• Biology to Prevention Award
• View all schemes and deadlines

Applying for funding

• Start your application online
• How to make a successful application
• Funding committees
• Successful applicant case studies

How we deliver research

• Our research infrastructure
• Events and conferences
• Our research partnerships
• Facts & figures about our funding
• Develop your research career
• Recently funded awards
• Manage your research grant
• Notify us of new publications

Find a shop

• Volunteer in a shop
• Donate goods to a shop
• Our superstores

Shop online

• Wedding favours
• Cancer Care
• Flower Shop

Our eBay store

• Shoes and boots
• Bags and purses
• We beat cancer
• We fundraise
• We develop policy
• Our global role

Our organisation

• Our strategy
• Our Trustees
• CEO and Executive Board
• How we spend your money
• Early careers

Cancer news

• Cancer News
• For Researchers
• For Supporters
• Press office
• Publications
• Update your contact preferences

ABOUT CANCER

GET INVOLVED

NEWS & RESOURCES

FUNDING & RESEARCH

You are here

Consent forms for SACT (Systemic Anti-Cancer Therapy)

Useful links

Patient information about cancer drugs 

Immunotherapy and its side effects  

About cancer registration  

Patient information about your type of cancer   

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms.

We want to support clinicians in ensuring all patients are fully informed when consenting to SACT. These forms are endorsed by the UK Systemic Anti-Cancer Therapy Board (UK SACT Board).

Who has approved the content in these forms?

The programme is being led by a dedicated Cancer Research UK funded oncology pharmacist at Guys’ and St. Thomas’ NHS Foundation Trust.

All forms are independently checked by an oncology/haematology pharmacist, oncology/haematology consultant and member of the UK SACT Board.

The consent forms and guidance document are available to download in PDF format. Forms are grouped by tumour-site.

If you have specific queries or are looking for something not covered here, please email the pharmacist.

[email protected]

SACT Form update

SACT consent forms are currently being reviewed on a rolling schedule. Please see FAQs for order of roll-out. Republication dates may exceed the date of review indicated on each form. All forms are valid until new versions are available.

What's new?

• 27th March 2024: Sarcoma – New consent forms uploaded
• 22nd March 2024: Acute Lymphoblastic Leukaemia (ALL) – New consent forms uploaded
• 21st March 2024: Guidance on electronic consent for SACT reviewed and updated
• 15th March 2024 : Skin cancer (non-melanoma) SACT consent forms updated
• 29th December 2023 : Updates to Lenvatinib and Atezolizumab + Bevacizumab for HPB
• 20th December 2023 : Updates to Venetoclax + Ibrutinib and Ibrutinib for CLL
• 7th December 2023:  New form added for Pembrolizumab
• 14th November 2023 : Updates to CLL, Generic SACT consent and Generic checkpoint inhibitor immunotherapy forms
• 14th September 2023 : New form added for Pazopanib
• 18th August 2023 : Updated lung, breast, GIST and AML Azacitidine SACT consent forms
• 10th August 2023 : Updated Children and Young People, Kaposi sarcoma and CML SACT consent forms
• 25th July 2023 : Updated Temozolomide and Temozolomide + RT for brain and CNS
• 12th May 2023:  Brain and CNS SACT consent forms updated and a new form added for Ibrutinib

Frequently Asked Questions (FAQs)

Which tumour site group’s forms are available and when will they be reviewed.

The regimen-specific forms have been published for the following tumour site groups. Each group of forms will be reviewed on a rolling schedule every three years. The process by which each group of forms is revalidated may result in the republication dates exceeding the date of review indicated on each group of forms. All forms are valid until new versions are made available.

Please check the website regularly (e.g. once a month) for new forms and updates.

What happens when a new regimen is commissioned before the consent form group is due to be revalidated?

We are working to develop and publish consent forms in time with publication of positive NICE (England), AWMSG (Wales), SMC (Scotland) and HSCNI (Northern Ireland) determinations.

What should I do if I cannot find the regimen-specific form that I need?

We encourage Trusts to use the generic SACT or immunotherapy forms where a regimen-specific form is not available. Please get in touch with the project lead pharmacist so that this can be discussed with the tumour-specific lead consultant for development. Contact details for the project lead pharmacist are found at the end of this document.

When will consent forms for the haematology groups be available?

CML, CLL, MPN, and AML consent forms have now been published. ALL, lymphoma and myeloma consent forms are in development.

How have the forms been developed and what is the governance process?

The forms are based on the Department of Health consent form 1. The template form has been approved by the UK Systemic Anti-Cancer Therapy Board. Each hospital/Trust will need to ensure that the forms are approved for use locally by their governance or consent committee, whichever is most appropriate for the individual organisation. Please refer to the Guidance on Consent for SACT available on this website here .

Are the consent forms a legal document? 

The consent form is not a legal document, but it represents best practice and conforms with and complements the guidance documents available to clinicians taking consent. Several guidance documents have described best practice in the area of consent with respect to law, ethics, training and experience required and the need for documentation that consent has taken place.

We explored informal counsel with a medico-legal advisor, in response to the issue of the Montgomery judgement. The following has been taken from their reply:

The consent forms are developed to ensure a high level of consistency in the information giving and discussion with the patient. Your Trust Governance and/or consent committee must agree before you use these forms.

How do I give a copy of the completed form to the patient?

The patient can be given a photocopy or print out of the completed form. For trusts using electronic consent systems, there may be different mechanisms for providing the patient with a completed form depending on the system used, such as through secure email or a mobile application. We recommend retaining the original form in the patient’s records, or a scanned copy in the patient’s electronic records.  

Will the consent forms be made available electronically?

Due to the complexity of the IT infrastructure, numerous electronic patient records and SACT prescription systems across the NHS, the project team cannot provide one single national electronic consent solution. An electronic consent working group was subsequently formed as part of the project. The working group developed and published the ‘Guidance for the Implementation of CRUK SACT Consent Forms Electronically’. It is intended for use by NHS SACT providers wishing introduce electronic consent to decide which electronic consent solution would be the most appropriate for their individual needs. Guidance for the configuration and maintenance of electronic consent forms, including adoption of the CRUK consent forms electronically, is provided in this document. The document can be found on the CRUK SACT consent form webpage under the accordion ‘Guidance on Electronic Consent for SACT’ here .

Can I use the CRUK consent forms, branding and footer on our local electronic consent system?

The CRUK regimen-specific consent forms may be used within local electronic consent systems. As the forms have been through a robust governance process to ensure their consistency and quality, the following disclaimers should be used depending on the applicable scenario. The following disclaimers will be included in the next version of the Guidance on Electronic Consent along with CRUK brand guidelines for logo use.

Use of the consent forms without amendments:

The CRUK logo and consent form footer can be included in electronic consent forms where the content of the forms is used unamended in its entirety. The format, font or colours can be changed if necessary, but the text and CRUK logo should be unamended. The footer at the bottom of each page of the consent form includes the names of those who have prepared, checked and approved the forms, as well as the details of version and date.

In this instance, please include the following disclaimer:

When amendments are made to the consent form contents:

Where providers base their electronic consent forms on the CRUK consent forms but change some of the content for technical or clinical reasons, the CRUK logo and consent form footer should not be used.

The following disclaimer should be included within the e-consent system in a way that makes it clearly visible to both clinician and patient.

Will the consent forms be made available in Welsh and/or other languages?

The generic SACT and generic immunotherapy consent forms have been translated to Welsh. It is recommended that these forms are used to supplement the English regimen-specific consent forms when a Welsh language accompaniment is required. The project team continues to investigate avenues through which the translation of consent forms can be achieved.

Will chemo-radiotherapy consent forms be developed?

These forms are designed specifically for taking consent for SACT. For instances where the SACT is given in combination with radiotherapy, the radiation therapy will need to be consented for separately. The Royal College of Radiologists (RCR) have developed national site-specific radiotherapy consent forms. These can be found here . The RCR plan to develop chemo-radiotherapy consent forms, but this is an ongoing piece of work for which timelines have not yet been confirmed.

Do you have children and young people (CYP) SACT consent forms?

The Children and Young People Generic Form was published in 2021. The ALL in Children and Young People form was subsequently published in 2023. We subsequently plan to develop national SACT regimen-specific consent forms for TYA groups.

Where can I find more information about the regimen-specific consent forms?

Further information can be found on www.cruk.org/sact_consent . You can also email [email protected] or [email protected] if you have any queries and with any comments.

Download these FAQs

Last updated: 9 January 2024

Guidance on consent for SACT

Guidance on remote consent for SACT

Guidance for SACT by Healthcare Improvement Scotland

Guidance on Electronic Consent for SACT v02

Last updated: 7th September 2021

Generic forms

Generic SACT form

Generic checkpoint inhibitor immunotherapy form

Welsh Generic SACT form

Welsh Generic Immunotherapy form

Last updated: 14th November 2023

Children and Young People (age 0-24 years)

ALL in Children and Young People

Children and Young people generic form

Last updated: 10th August 2023

Acute Lymphoblastic Leukaemia (ALL)

Blinatumomab

Clofarabine, Cyclophosphamide and Etoposide

Inotuzumab Ozogamicin

Nelarabine, Cyclophosphamide and Etoposide

UKALL14 Consolidation 1,2 and 4

UKALL14 Consolidation 3

UKALL 14 Intensification CNS Prophylaxis

UKALL 14 Maintenance

UKALL 14 Phase 1 Induction

UKALL 14 Phase 2 Induction

UKALL 14 Intrathecal Systemic Anti-Cancer Therapy

UKALL 60+ Intensive (Philadelphia Negative)

UKALL 60+ Non-Intensive Intensive (Philadelphia Negative)

UKALL 60+ Philadelphia Positive

Download all Acute Lymphoblastic Leukaemia (ALL) forms

Last updated: 22 March 2024

Acute Myeloid Leukaemia (AML)

Azacitidine

Azacitidine +  Venetoclax

AIDA (All- transretinoic acid and Idarubicin)

ATRA (All-transretinoic acid)

High dose cytarabine (ARA C) + Amsacrine

DA (Daunorubicin and Cytarabine)

Etoposide (po)

Gemtuzumab ozogamicin with daunorubicin and cytarabine

FLAG - Idarubicin

Gilteritinib

Gemtuzumab +  chemotherapy

High dose cytarabine (ARA C)

Hydroxycarbamide

Liposomal daunorubicin + Cytarabine ( Vyxeos)

Low dose cytarabine ( ARA C)

Low dose cytarabine ( ARA C) + Venetoclax

Midostaurin + chemo (DA + HD Ara C)

Midostaurin (+/- chemotherapy)

Mitoxantrone

Download all AML cancer SACT forms

Last updated: 17th August 2023

Brain/CNS cancers

Carboplatin-Etoposide

Procarbazine-Lomustine-Vincristine (PCV)

Temozolomide

Temozolomide+Radiotherapy

Download all Brain/CNS cancers SACT forms

Last updated: 25th July 2023

Breast cancers

AC (Doxorubicin-Cyclophosphamide)

Abemaciclib

AC-Docetaxel

Atezolizumab - Paclitaxel albumin-bound

Bevacizumab

Capecitabine

Carboplatin

Cyclophosphamide-Methotrexate

Docetaxel-Capecitabine

Doxorubicin

EC (Epirubicin-Cyclophosphamide)

EC-Carboplatin-Paclitaxel

EC-Docetaxel

EC-Docetaxel-Trastuzumab

EC-Paclitaxel

EC-Paclitaxel-Trastuzumab

Epirubicin-CMF

FEC-Docetaxel-Trastuzumab

FEC-Paclitaxel-Trastuzumab

FEC-PPH (Paclitaxel-Pertuzumab-Trastuzumab)

FEC-TPH (Docetaxel-Pertuzumab-Trastuzumab)

Gemcitabine-Carboplatin

Gemcitabine-Paclitaxel

Kadcyla® (trastuzumab emtansine)

Liposomal doxorubicin (Myocet®)

Liposomal doxorubicin (Myocet®)-Cyclophosphamide

Paclitaxel albumin-bound

Paclitaxel albumin-bound - Carboplatin

Paclitaxel-Trastuzumab

Palbociclib

Pertuzumab-Trastuzumab

TC (Docetaxel-Cyclophosphamide)

TCarboH (Docetaxel-Carboplatin-Trastuzumab)

TCarboPH (Docetaxel-Carboplatin-Pertuzumab-Trastuzumab)

TPH (Docetaxel-Pertuzumab-Trastuzumab)

Trastuzumab

Trastuzumab Deruxtecan

Tucatinib, trastuzumab and capecitabine

Vinorelbine (IV)

Vinorelbine (Oral)

Vinorelbine-Capecitabine

Last updated: 18th August 2023

Chronic Lymphocytic Leukaemia (CLL)

Acalabrutinib

Bendamustine – Rituximab

Chlorambucil

Chlorambucil – Obinutuzumab

Chlorambucil – Rituximab

FCR (Fludarabine – Cyclophosphamide – Rituximab) 3 Days

FCR (Fludarabine – Cyclophosphamide – Rituximab) 5 Days

Idelalisib – Rituximab

Venetoclax – Ibrutinib

Venetoclax – Rituximab

Venetoclax – Obinutuzumab

Zanubrutinib

Download all chronic lymphocytic leukaemia cancer SACT forms

​Last update: 20th December 2023

Chronic Myeloid Leukaemia (CML)

Interferon-Alfa

Peginterferon-Alfa

Download all chronic myeloid leukaemia cancer SACT forms

Colorectal cancer

Aflibercept irinotecan-fluorouracil folfiri, bevacizumab chemotherapy, capecitabine mitomycin, capecitabine-mitomycin radiotherapy.

Capecitabine and Radiotherapy

Carboplatin and Paclitaxel

Cetuximab +/- chemotherapy, cisplatin-capecitabine.

Cisplatin-Fluorouracil

Encorafenib and Cetuximab

Fluorouracil Modified de Gramont

Fluorouracil and folinic acid weekly, fluorouracil pvi +/- radiotherapy, irinotecan capecitabine (capiri), irinotecan fluorouracil (folfiri), mitomycin-fluorouracil radiotherapy, nivolumab and ipilimumab.

Oxaliplatin-Capecitabine (CAPOX)

Oxaliplatin-Fluorouracil_(FOLFOX)

Oxaliplatin-irinotecan-fluorouracil (folfoxiri), oxaliplatin-raltitraxed (tomox), panitumumab +/- chemotherapy.

Pembrolizumab

Raltitrexed

Regorafenib

Trifluridine and Tipiracil (lonsurf®)

Download all colorectal cancer SACT forms

Last updated: 14 July 2022

Gastrointestinal stromal tumors (GIST)

Download all gastrointestinal stromal tumours (GIST) SACT forms 

Gynaecological cancers

BEP (5 day)

Carboplatin-Paclitaxel

Cisplatin + Radiotherapy

Cisplatin-Etoposide

Cisplatin-Fluorouracil + Radiotherapy

Cisplatin-Paclitaxel

Cisplatin-Topotecan

Doxorubicin-Cisplatin

EP (Etoposide-Cisplatin)

Etoposide (oral)

Gemcitabine

Gemcitabine-Cisplatin

Liposomal doxorubicin (Caelyx®)

Liposomal doxorubicin (Caelyx®) - Carboplatin

Paclitaxel (day 1, 8 & 15)

Topotecan (IV)

Download all gynaecological cancers SACT forms

Last updated: 16 February 2021

Head and neck cancers

Carboplatin + Radiotherapy

Carboplatin-Fluorouracil

Cetuximab - Carboplatin - Fluorouracil

Cetuximab - Cisplatin - Fluorouracil

Cetuximab + Radiotherapy

ECarboF (epirubicin-carboplatin-fluorouracil)

Methotrexate

TCarboF (docetaxel-carboplatin-fluorouracil)

TPF (docetaxel-cisplatin-fluorouracil)

Download all head and neck cancers SACT forms

Last updated: 5th September 2022

Hepato Pancreato Biliary (HPB) cancers

Atezolizumab and Bevacizumab

Capecitabine + Radiotherapy

Fluorouracil (Modified de Gramont)

Gemcitabine-Capecitabine

Gemcitabine-Paclitaxel albumin-bound (Abraxane®)

Oxaliplatin-Fluorouracil (FOLFOX)

Download all Hepato Pancreato Biliary (HPB) SACT forms

Last updated: 29th December 2023

Kaposi sarcoma

Pegylated Liposomal Doxorubicin (Caelyx)

Download all Kaposi Sarcoma SACT forms

Last updated 10th August 2023

Atezolizumab, bevacizumab, carboplatin and paclitaxel

Atezolizumab, carboplatin and etoposide

Atezolizumab

CAP (cyclophosphamide-doxorubicin-cisplatin)

Carboplatin, pemetrexed and pembrolizumab

Carboplatin, paclitaxel and pembrolizumab

Carboplatin-Pemetrexed

Carboplatin-Vinorelbine

CAV (cyclophosphamide-doxorubicin-vincristine)

Cisplatin-Pemetrexed

Cisplatin- pemetrexed - pembrolizumab

Cisplatin-Vinorelbine

Dacomitinib

Larotrectinib

Nintedanib-Docetaxel

Osimertinib

Pemetrexed (maintenance)

Ramucirumab-Docetaxel

Selpercatinib

Topotecan (oral)

Vinorelbine (oral)

Download all lung cancer SACT forms

Melanoma skin cancer

CVD (cisplatin-vinblastine-dacarbazine)

Dabrafenib-Trametinib

Dacarbazine

Encorafinib-Binimetinib

Ipilimumab-Nivolumab

Talimogene laherparepvec (Imlygic®)

Vemurafenib

Vemurafenib-Cobimetinib

Download all melanoma skin cancer SACT forms

Myeloproliferative Neoplasms (MPN)

Interferon alfa

Ruxolitinib

Thalidomide

Download all Myeloproliferative Neoplasms (MPN) SACT forms

​Last updated: 21 June 2019

Neuroendocrine and adrenal cancers

Cyclophosphamide-Vincristine-Dacarbazine (CVD)

Etoposide-Doxorubicin-Cisplatin (EDP) +/- Mitotane

Irinotecan-Fluorouracil (FOLFIRI)

Streptozocin-Capecitabine

Streptozocin-Cisplatin-Fluorouracil

Temozolomide-Capecitabine

Download all Neuroendocrine and adrenal cancers SACT forms

The published forms listed here are not exhaustive for neuroendocrine cancers. They reflect mostly (but not exclusively) those regimens for gastroenteropancreatic neuroendocrine tumours.  The regimen-specific consent forms for neuroendocrine cancers of other areas of the body can be found within their respective anatomical groups.

Last updated: 15 February 2019

Oesophago-gastric cancers

Capecitabine-Cisplatin + Radiotherapy

Cisplatin-Capecitabine-Trastuzumab

Cisplatin-Fluorouracil (+/- Radiotherapy)

Cisplatin-Fluorouracil-Trastuzumab

Docetaxel-Oxaliplatin-Fluorouracil (FLOT)

ECarboX (epirubicin-carboplatin-capecitabine)

ECF (epirubicin-cisplatin-fluorouracil)

ECX (epirubicin-cisplatin-capecitabine

EOF (epirubicin-oxaliplatin-fluorouracil)

EOX (epirubicin-oxaliplatin-capecitabine)

Fluorouracil PVI + Radiotherapy

Paclitaxel-Carboplatin + Radiotherapy

Download all oesophago-gastric cancers SACT forms 

Last updated: 20 December 2018

Carboplatin - Etoposide

Cyclophosphamide - Etoposide

Cyclophosphamide - Oral prednisolone

Cyclophosphamide - Topotecan

Doxorubicin - Cisplatin

Doxorubicin - Dacarbazine

Doxorubicin - Ifosfamide

Etoposide (Oral)

Gemcitabine - Dacarbazine

Gemcitabine - Docetaxel

IE and Methotrexate

IVADo - IVA

Mifamurtide

Pegylated Liposomal Doxorubicin and Ifosfamide

Pegylated Liposomal Doxorubicin

Trabectedine

Vincristine and Cyclophosphamide

Vinorelbine and Cyclophosphamide

Download all Sarcoma forms

Last updated: 27 March 2024

Thyroid cancer

Cabozantinib

Dabrafenib and Trametinib

Entrectinib

Download all thyroid cancer SACT forms

Last updated: 5 April 2022

Urology-Bladder cancer

Accelerated M-VAC (methotrexate-vinblastine-doxorubicin-cisplatin)

Gemcitabine-Radiotherapy

Mitomycin-Fluorouracil +/- Radiotherapy

M-VAC (methotrexate-vinblastine-doxorubicin-cisplatin)

Download all urology-bladder cancers SACT forms

Last updated: 03 August 2022

Urology-Germ cell cancer

BEP (Bleomycin-Etoposide-Cisplatin)

Carboplatin (Etoposide-Bleomycin)

TIP (Paclitaxel-Ifosfamide-Cisplatin)

VIP (Etoposide-Ifosfamide-Cisplatin)

VeIP (Vinblastine-Ifosfamide-Cisplatin)

Download all urology-germ cell cancer SACT forms

Last updated: 20 April 2021

Urology-Prostate cancer

Abiraterone + Prednisolone

Apalutamide

Cabazitaxel + Prednisolone

Darolutamide

Docetaxel + Prednisolone

Enzalutamide

Download all urology-prostate cancer SACT forms

Last updated: 16th August 2022

Urology-Renal cell cancer

Generic TKI & IO

Avelumab - Axitinib

Gemcitabine-Doxorubicin

Lenvatinib-Everolimus

Nivolumab - Ipilimumab

Download all Urology-Renal cell cancer SACT forms

Last updated: 7th December 2023

Urology-Small cell cancer

Download all Urology-Small cell cancer SACT forms

Last updated: 10 August 2021

Skin cancer (non-melanoma)

Alemtuzumab

Capecitabine-Cisplatin

Chlorambucil +/- Prednisolone

CHOP 21 + Rituximab (CHOP-R)

CVP (Cyclophosphamide-Vincristine-Prednisolone)

Interferon alfa-2a (Roferon-A®)

Liposomal Doxorubicin (Caelyx®)

Methotrexate (Oral)

Pentostatin

Vismodegib  

Download all skin cancer (non-melanoma) SACT forms

Last updated: 15 March 2024

Supportive medicines

Denosumab (Xgeva®)

Zoledronic acid

Download all supportive medicines forms

Last updated: 07 August 2020

Publishing, additions and updates

We are publishing forms by tumour site, the first were for breast cancer in May 2016. We will publish new forms for other tumour sites regularly.

Recent additions and updates will be highlighted on the "What's new?" section on this page, and details of when forms have been last updated is stated in each section. Please check for updated versions and ensure that you use the latest version of each form.

Join us on X (previously known as Twitter)

Read a world first population based study of 30-day mortality following SACT in England

Read our blog on the study’s findings and how the work will help improve patient case

View the NHS Trust and national SACT 30-day mortality data published by Public Health England

404 Not found

You are using an outdated browser. Please upgrade your browser or activate Google Chrome Frame to improve your experience.

• Discover pathology

National Guidance on consent for Systemic Anti-Cancer Therapy (SACT) - Chemotherapy

24 July 2016

The National Chemotherapy Board and Cancer Research UK are pleased to launch the Guidance on the consent for SACT and national SACT regimen-specific consent forms . The aim of the guidance and forms is to support clinicians to ensure that patients receiving SACT are fully informed when consenting to treatment.

The guidance document encompasses:

• Background to consent for SACT
• National Chemotherapy Board recommendations and the national regimen-specific consent forms
• Guidance for the introduction of the national regimen-specific consent forms by individual chemotherapy providers, e.g. gaining approval from your Trust governance/consent committees
• Guidance for the process of consent for SACT
• Recommendations for the audit of consent procedures

Documentation can be accessed and downloaded from the Cancer Research UK website: www.cruk.org/sact_consent . 

Michelle Dominique

• Administrator

• ACP - Association of Cancer Physicians on Twitter

National Regimen-Specific Consent Forms - Publication Updates

Posted on 1 June 2020

Regimen-specific consent forms for many tumour types have been published on the Cancer Research UK website , more tumour-site and regimen specific and generic forms now released, including, as below:

• Breast cancer
• Colorectal cancer
• Upper Gastrointestinal cancer (OG, HPB and GIST)
• Gynaecology cancers
• Head & Neck cancers
• Lung cancer
• Melanoma skin cancer
• Thyroid cancer
• Urology cancers (bladder and prostate)
• Supportive therapies

SACT consent forms are reviewed and updated on a rolling basis.  The most recent updates have been to the breast and gynae forms. Many of the new forms contain a combination of drugs so that in most instances only one consent form needs to be completed.

Changes have also been made to the individual regimen specific consent forms, in response to updated information or clinicians request for clarity.

For more detail please see our Resources section.

• 2024-02-29 National Clinical Impact Awards 2024 (England and Wales)
• 2024-02-29 BEST OF ASCO® 2024 UK LIVE Event 21 June, London
• 2024-02-29 SACT Capacity Crisis
• 2024-01-08 ACP New Consultants Group, Birmingham 1-2 March
• 2024-01-03 Webinar on Training in Medical Oncology
• 2023-08-25 ACP and UKAOS Acute Oncology Workshop 10 November
• 2023-08-03 Report and Recommendations of the Clinical Oncology and Medical Oncology Closer Working Group
• 2023-07-05 Best of ASCO® UK
• 2023-07-03 Webinar on Training in Medical Oncology
• 2023-06-16 REVISION BOOK - 500 SBAs for the SCE
• ©ACP - Association of Cancer Physicians
• Term & Conditions
• Privacy & Cookies
• Site by Plexus

404 Not found

SACT consent forms on Cancer Research UK website

National Systemic Anti-Cancer Therapy (SACT) consent forms – for urology (germ cell), breast and oesophago-gastric cancers published.

Regimen-specific consent forms for the following tumour groups have been published on the Cancer Research UK website:

·          Breast cancer – 3 forms added

o    Palbociclib

o    Pertuzumab-Trastuzumab version-2

o    Ribociclib

·          Urology-Germ Cell cancers – 6 forms

·          Oesophago-gastric cancer – 1 form added

o    Capecitabine-Cisplatin+Radiotherapy

Please visit www.cruk.org/sact_consent to view and download the forms.   Other forms, national guidance on consent for SACT, and further information is also available via www.cruk.org/sact_consent .

Please do not hesitate to contact Victoria Fashina (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: [email protected]

Victoria Fashina

12 April 2018

Latest News

Published: bopa delphi consensus guidelines.

The BOPA Guidelines, Advocacy And Publications Committee is pleased to announce that the British Oncology Pharmacy Association Delphi consensus guidelines is now published on the Journal of Oncology Pharmacy Practice.…

REGISTER NOW: #BOPA2024 Annual Conference @ICC Birmingham and AGM 2024

The 27th British Oncology Pharmacy Association (BOPA) Annual Conference, 11-13 October 2024, ICC Birmingham   We are pleased to announced that the registration for the BOPA Annual Conference 2024 is now open. The…

CRUK Sarcoma regimen specific SACT consent forms are now available

I am very pleased to inform you that the Sarcoma regimen specific consent forms are now available on the CRUK website. The forms can be found at https://www.cancerresearchuk.org/health-professional/treatment-and-other-post-diagnosis-issues/consent-forms-for-sact-systemic-anti-cancer-therapy?1z Any questions,…

Apply now for the Cancer Research Transatlantic Development and Skills Enhancement Award

Are you a UK early to mid-career researcher focussed on cancer? You could gain new research skills and develop international collaborations with a funded placement at a world-class cancer institute…

27th BOPA Conference 2024

The 27th BOPA Annual Conference in 2024 will be held at the ICC Birmingham on 11-13 October.

Check out the latest information here: https://www.bopa.org.uk/latest-Conference-2024/

Recommended pages

• Undergraduate open days
• Postgraduate open days
• Accommodation
• Information for teachers
• Maps and directions
• Sport and fitness

Informed Consent Forms

Below is a link to the current Informed Consent Forms

• ParentGuardian_Trial Entry_1.0_07Aug2015  [.doc]
• ParentGuardian_Dose Finding Study_1.0_07Aug2015  [.doc]
• ParentGuardian_Trial Entry_plus One Dose of Mylotarg_1.0_20-Feb-2017 [.doc]
• ParentGuardian_Subsequent Randomisations_1.0_07Aug2015  [.doc]
• Patients Aged 16+ Years_Trial Entry_1.0_07Aug2015  [.doc]
• Patients Aged 16+ Years_Dose Finding Study_1.0_07Aug2015  [.doc]
• Patients Aged 16+ Years_Trial Entry_plus One Dose of Mylotarg_1.0_20-Feb-2017 [.doc]
• Patients Aged 16+ Years_Subsequent Randomisations_1.0a_07Aug2015  [.doc]

• IOCN Policies & Governance
• Disclaimer and Conditions of Use Policy
• IO Toxicity Guidelines
• Specialist Support
• Case Series
• Patient Information
• Consent Forms
• Videos for Patients
• National IO Education Forum
• Case of the Month
• Education Ethos
• Educational Events
• Immunobuddies Podcast
• Policy & Governance
• Translational Research
• Service Development

@IOClinicalNet

• Clinical Support
• Education & Training
• Research & Analysis

The Immuno-Oncology Clinical Network

Consent forms , cancer research uk (cruk) consent forms for systemic anti-cancer treatment (sact).

Immunotherapy regimens:

• Atezolizumab
• Ipilimumab and Nivolumab
• Pembrolizumab

Immunotherapy combination treatment:

• Atezolizumab, Bevacizumab, Caroplatin and Paclitaxel
• Atezolizumab, Caroplatin and Etoposide
•  Avelumab and Axitinib
• Carboplatin, Paclitaxel and Pembrolizumab
• Carboplatin, Pemetrexed and Pembrolizumab
• Cisplatin, Pemetrexed and Pembrolizumab

Registered Charity Number:

Join Us: Become a Member of the IOCN

IOCN Disclaimer and Conditions of Use Policy